(Q46818665)

25 December 2017

title

Caffeine is protective in patients with non-alcoholic fatty liver disease (English)

1 reference

25 December 2017

non-alcoholic fatty liver

main subject

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

A Birerdinc

1

1 reference

25 December 2017

M Stepanova

series ordinal

2

1 reference

25 December 2017

L Pawloski

series ordinal

3

1 reference

25 December 2017

Z M Younossi

series ordinal

4

1 reference

25 December 2017

language of work or name

English

0 references

publication date

7 November 2011

1 reference

25 December 2017

Alimentary Pharmacology & Therapeutics

published in

1 reference

25 December 2017

volume

35

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

76-82

1 reference

25 December 2017

Nonalcoholic fatty liver disease

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Diagnosis and therapy of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Nonalcoholic fatty liver disease: a review of current understanding and future impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Hepatic histology in obese patients undergoing bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Prevalence and trends in obesity among US adults, 1999-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Bariatric surgery for non-alcoholic steatohepatitis in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Unexpected effects of coffee consumption on liver enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Distribution and population determinants of gamma-glutamyltransferase in a random sample of Sardinian inhabitants. 'ATS-SARDEGNA' Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Determinants of gamma-glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Coffee intake and mortality from liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Increased caffeine consumption is associated with reduced hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Pathology of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Effects of coffee on inflammatory cytokine gene expression in mice fed high-fat diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Coffee and caffeine ameliorate hyperglycemia, fatty liver, and inflammatory adipocytokine expression in spontaneously diabetic KK-Ay mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Freeze-dried instant coffee can promote the activities of antioxidant enzymes and induce weight loss but also aggravate the plasma cholesterol profile in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04916.X

10.1111/J.1365-2036.2011.04916.X

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

release_7rifr6ii4fcrpdx3xm7ur6bvoa

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7rifr6ii4fcrpdx3xm7ur6bvoa

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22059453

1 reference

25 December 2017